PRESS RELEASES<< Back
Chimerix to Host Annual Investor Update on October 17, 2018
In addition to presentations from management, the event will feature a keynote presentation from Roy F. Chemaly, MD, MPH, Professor,
To access the live webcast, please visit the Investor Relations section of Chimerix's website at ir.chimerix.com. An archived replay of the webcast will also be available at the same location.
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
Source: Chimerix, Inc.